Mechanism of IL-10 Pathway-mediated Regulatory B Cell Dysfunction in Osteoarthritis
Launched by SHUFENG LI · Jan 18, 2024
Trial Information
Current as of March 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria:Patients who met the American College of Rheumatology diagnostic criteria for OA
- • -
- Exclusion Criteria:
- • Patients with trauma, other forms of arthritis such as rheumatoid arthritis, psoriatic arthritis or spondyloarthritis, and other active inflammatory diseases
About Shufeng Li
Shufeng Li is a distinguished clinical trial sponsor dedicated to advancing medical research and innovative therapies. With a strong commitment to improving patient outcomes, the organization specializes in the design and execution of clinical trials across various therapeutic areas. Shufeng Li employs a rigorous scientific approach, leveraging cutting-edge methodologies and a collaborative network of healthcare professionals to ensure the highest standards of ethical conduct and compliance. Their focus on transparency, patient safety, and robust data integrity positions them as a trusted partner in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
